PMID- 34904087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211215
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 9
IP  - 33
DP  - 2021 Nov 26
TI  - Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its 
      potential benefits.
PG  - 10172-10179
LID - 10.12998/wjcc.v9.i33.10172 [doi]
AB  - BACKGROUND: Secondary hyperparathyroidism (SHPT) is a common complication in 
      patients with end-stage renal disease and it is also common in hemodialysis 
      patients. SHPT can increase bone fragility and calcification of blood vessels and 
      soft tissues, which greatly increases the risk of death. AIM: To discuss the 
      outcome, safety and other potential benefits of paricalcitol injection in 
      hemodialysis patients with SHPT. METHODS: We recruited 40 patients who received 
      hemodialysis at our hospital for chronic renal failure with SHPT between March 
      and December 2019. They received paricalcitol injection for 24 wk (starting dose, 
      0.06-0.08 mug/kg), three times per week. They were followed up at the baseline 
      (week 0), week 4, week 12 and week 24. The primary outcome indicator was the 
      percentage of patients with a > 30% decrease in intact parathyroid hormone (iPTH) 
      levels at week 24 compared with the baseline. The secondary outcome indicators 
      included percentage decrease in iPTH levels at week 24, standard-reaching rate of 
      iPTH (percentage of patients with iPTH down to 130-585 pg/mL), changes in serum 
      levels of calcium (Ca), phosphate (P), Ca x P product, alkaline phosphatase 
      (ALP), creatinine (Cre), hemoglobin (Hb), and C-reactive protein (CRP), and 
      incidence of adverse events (AEs). RESULTS: After 24 wk of treatment, iPTH levels 
      decreased significantly (598.88 +/- 381.29 pg/mL vs 888.84 +/- 376.88 pg/mL, P < 
      0.05). More than 30% decrease of iPTH was found in 21 of 36 (58.33%) patients. 
      The average decrease in iPTH levels was 32.16 +/- 4.33%; the standard-reaching rate 
      of iPTH levels was 66.67% (24/36); and ALP levels decreased significantly 
      compared with the baseline (113.72 +/- 41.73 IU/L vs 133.45 +/- 56.86 IU/L) (t = 
      2.798, P < 0.05). There were no significant differences in the serum levels of 
      calcium, Hb, Cre and CRP compared with the baseline (P > 0.05). After 24 wk of 
      treatment, serum P levels decreased compared with the baseline (1.91 +/- 0.40 
      mmol/L vs 2.16 +/- 0.66 mmol/L) (t = 2.830, P < 0.05). Ca x P product decreased 
      significantly compared with the baseline (56.38 +/- 13.22 mg(2)/dL(2) vs 63.97 +/- 
      20.30 mg(2)/dL(2)) (t = 2.717, P < 0.05). No serious adverse events occurred. 
      CONCLUSION: Paricalcitol was a safe and effective treatment for hemodialysis 
      patients with SHPT. It decreased serum levels of iPTH, ALP and P and maintained 
      stability of serum Ca levels.
CI  - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Chen, Xiu
AU  - Chen X
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China.
FAU - Zhao, Feng
AU  - Zhao F
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China.
FAU - Pan, Wei-Juan
AU  - Pan WJ
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China.
FAU - Di, Jia-Mei
AU  - Di JM
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China.
FAU - Xie, Wei-Nan
AU  - Xie WN
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China.
FAU - Yuan, Ling
AU  - Yuan L
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China.
FAU - Liu, Zhi
AU  - Liu Z
AD  - Department of Nephrology, The First Affiliated Hospital of Anhui University of 
      Science and Technology (The First People's Hospital of Huainan), Huainan 232007, 
      Anhui Province, China. hnsnk@163.com.
LA  - eng
PT  - Clinical Trial
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC8638032
OTO - NOTNLM
OT  - Drug efficacy
OT  - Drug safety
OT  - Hemodialysis
OT  - Paricalcitol
OT  - Secondary hyperparathyroidism
COIS- Conflict-of-interest statement: The authors declared that they have no conflicts 
      of interest to this work.
EDAT- 2021/12/15 06:00
MHDA- 2021/12/15 06:01
PMCR- 2021/11/26
CRDT- 2021/12/14 08:23
PHST- 2021/07/07 00:00 [received]
PHST- 2021/08/12 00:00 [revised]
PHST- 2021/10/14 00:00 [accepted]
PHST- 2021/12/14 08:23 [entrez]
PHST- 2021/12/15 06:00 [pubmed]
PHST- 2021/12/15 06:01 [medline]
PHST- 2021/11/26 00:00 [pmc-release]
AID - 10.12998/wjcc.v9.i33.10172 [doi]
PST - ppublish
SO  - World J Clin Cases. 2021 Nov 26;9(33):10172-10179. doi: 
      10.12998/wjcc.v9.i33.10172.